The First Mitochondrial Targeted Agent to Treat Neurodegenerative Diseases Blue Bell, Pennsylvania (BUSINESS WIRE) — Mitochon Pharmaceuticals today announced completion of its second year of funding with a total investment of $1.6 million. The proceeds from the financing will be used to advance Mitochon’s lead compound MP101, a first in class mitochondrial targeted neuro…(Read More)